Comparison of Two Marketed Hydroxypropyl Methylcellulose Based Artificial Tear Drops in Young Patients with Dry Eye Syndrome
Novelty in Biomedicine,
Vol. 3 No. 4 (2015),
28 October 2015
Background: Artificial tears have been among the first line of therapy in management of Dry Eye Syndrome (DES). This study was conducted to compare a local artificial tear with an imported one in reduction of DES. This comparison would help to evaluate the cost and benefits of each drop in the proper management of DES.
Materials and Methods: In this double-blind randomized clinical trial study, a total 65 students meeting our inclusion criteria for DES entered the study. The OSDI questionnaire, TBUT, corneal and conjunctival staining and Schirmer test, were performed. The patients were divided into two groups by block randomization. Group 1 received first drop and group 2 received second drop. Both groups were instructed to use the drops 4 times a day for 14 days. The same tests were performed by the same examiner who was blind to the treatment type after two weeks. Repeated measured ANOVA was used to analyze the data.
Results: A total of 58 patients completed the study. In both groups, after the intervention, the OSDI scores (P<0.001), TBUT score (P=0.041), corneal (P<0.001) and conjunctival staining scores (P<0.001) showed improvement in compare to those before the intervention. However, the Schirmer test score did not show significantly difference before and after intervention. In comparing two groups the OSDI scores, the TBUT score, the corneal and conjunctival staining scores and the Schirmer scores did not show statistically significant difference.
Conclusion: The two artificial tears equally reduced the symptoms and signs of DES in two weeks.
- Dry eye syndrome
- Hydroxypropyl methylcellulose
- Artificial tear
How to Cite
Lemp MA, Foulks GN. The definition & Classification of Dry Eye Disease: Guidelines from the 2007 International Dry Eye Workshop. The Ocular Surface. http://tearfilm.org/pdfs/OM- Definition&Classification.pdf.
Chalmers RL, Begley CG. Repeatability of habitual symptoms as measured by the dry eye questionnaire (DEQ). Invest ophthalmol Vis Sci 2004 [E-Abstract 3455].
Schlote T, Kadner G, Frudenthaler N. Marked reduction and distinct pattern of eye blinking in patients with moderately dry eyes during video display terminal use. Graefes Arch Clin Exp Ophthalmol. 2004;242:306–12.
Burns DH. Characteristics of visual display units that may cause visual difficulties. Ophthalmic Physiol Opt. 1995;15:99-104.
Wolkoff P, Nøjaard JK, Troiano P and Piccoli B. Eye complaints in the office environment: precorneal tear film integrity influenced by eye blinking efficiency. Occup Environ Med. 2005;62:4–12.
Wolkoff P, Nøjaard JK, Franck C and Skove P. The modern office environments desiccate the eye? Indoor Air. 2006;16:258–65.
Kjæregaard SK, Hempel-Jørgensen A, Mølhave L, Andersson K, Juto JE and Stridh G. Eye trigeminal sensitivity, tear film stability, and conjunctival epithelium damage in 182-non-allergic, non-smoking Danes. Indoor Air. 2004;14:200–7
Wolkoff P, Kjæregaard SK. The dichotomy of relative humidity on indoor air quality. Environ Int. 2007;33:850–7.
Khurana AK, Choudhary R, Ahluwalia BK and Gupta S. Hospital epidemiology of dry eye. Indian J Ophthalmol. 1991;39:55–8.
Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol. 2010;21:310-6.
Li M, Gong L, Chapin WZ, Zhu M. Assessment of vision related quality of life in dry eye patients .Invest Ophthalmol Vis Sci. 2012;53:5722-7.
chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R and Wang JJ. Prevalence and associations of dry eye syndrome in an older population: the blue mountains Eye study. Clin Experiment Ophthalmol. 2003;31:229-32.
Galor A, Feuer W, Lee DJ, Florez H, Carter D, Pouyeh B, Prunty WJ and Perez VL. Prevalence and risk factors of dry eye syndrome in a United States veteran’s affairs population. Am J Ophthalmol. 2011;152:377-84.
Gue B, Lu P, Chen X, Zhang W and Chen R. Prevalence of dry eye disease in Mongolians at high altitude in china: the Henan eye study. Ophthalmic Epidemiol. 2010;17:234-41.
Jie Y, Xu L, Wu YYand Jonas JB. Prevalence of dry eye among adults Chinese in the Beijing Eye Study. Eye (Lond). 2009;23:688-93.
Liew MS, Zhang M, Kim E and Akpek EK. Prevalence and predictors of sjogrens syndrome in a prospective cohort of patients with aqueous-deficient dry eye. Br J Ophthalmol. 2012; 96:1498-503.
Lin PY, Tsai SY, Cheng CY, Liu JH, Chou P and Hsu WM. Prevalence of dry eye among an elderly Chinese populations in Taiwan: the shihpai Eye Study. Ophthalmology. 2003;110:1096-101.
Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K and West S. Prevalence of dry eye among the elderly. AmJ ophthalmol. 1997;124:723-8.
Uchino M, Nishiwaki Y , Mishikawa T , Shirakawa K, Kuwahara E, Yamada M, Dogru M, Schaumberg DA, Kawakita T, Takebayashi T and Tsubota K. Prevalence and risk factors of dry eye disease in japan: Koumi Study. Ophthalmology. 2011;118:2361-7.
Uchino M, Schaumberg DA, Dogru M, Uchino Y, Fukagawa K, Shimmura S, Satoh T, et al. Prevalence of dry eye disease among Japanese visual display terminal users. Ophthalmology. 2008;115:1982-8.
Viso E, Rodriguez-Ares MT, Gude F. Prevalence of and associated factors for dry eye in a Spanish adult population (the salnes eye study). Ophthalmic epidemiol. 2009;16:15-21.
Zhang Y Chen H, Wu X. Prevalence and risk factors associated with dry eye syndrome among senior high school students in a county of Shandong province, china. Ophthalmic Epidemol. 2012;19:226-30.
Miki Uchino, Debra A. Schaumberg, Murat D Uchino Y, Fukagawa K, Shimmura S, Satoh T, Takebayashi T and Tsubota K. Prevalence of dry eye disease among Japanese visual display Terminal users. Department of ophthalmology, keio university school of medicine, Tokyo japan. 2008;115:11.
Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002;86:181-4.
Lin H, Yiu SC. Dry Eye Disease: A review of diagnostic approaches and treatments.Saudi Journal of Ophthalmology. 2014;28:173-81.
Waduthantri S, Yong SS, Tan CH, Liang SH, Lee MX, Natarajan S, Hla MH and Tong L. Cost of dry eye treatment in an Asian clinic setting. PLOS One. 2012;7:e37711.
Moshirfar M, Pierson K, Hanamaikai K, Santiago-Caban L, Muthappan B, Passi SF. Artificial tears potpourri: a literature review. Clinical Ophthalmology. 2014;8:1419-33.
Lemp MA, Goldberg M, Roddy MR. The effect of tear substitutes on tear film break up time. Invest Ophthalmol. 1975;14:255-8.
Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin ophthalmol. 2009;3:405-16.
Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch ophthalmol. 2000;118(5):615-21.
Donald R. Korb JC, Doughty M, Guillon JP, Smith G, Tomlinson A. The Tear Film: structure, function and clinical examination. Butterworth-Heinemann. 2002;138.
Lemp MA. Report of the National EYE Institution/Industry Workshop on Clinical Trials In dry Eyes. CLAO. 1995;21:221-32.
Donald R. Korb JC, Doughty M, Guillon JP, Smith G, Tomlinson A. The Tear Film: structure, function and clinical examination. Butterworth-Heinemann. 2002;114.
Toda I, Shinozaki N, Tsubutak. Hydroxypropylmethyl cellulose for the treatment of severe dry eye associated with sjogren syndrome. Cornea. 1996;15:120-8.
Nguyen T, Lutkeny R. Review of hydroxypropylmethyl cellulose inserts for treatment of dry eye. Clin ophthalmol. 2011;5:587-91.
Lanz R. Comparison of Genaqua-Preserved Genteal in multidose bottles vs Preservative-Free Tears Naturale in single dose units in patients with moderate to severe Dry Eye. Invest Ophthalmol Vis Sci. 2006;47:E-Abstract 259.
McCann LC, Tomilsone A, Pearce EI, Papa V. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea 2012;31:1-5.
Baudouin C, Labbe A, Liang H, Paul A, Brignole-Baudouin E. Preservatives in eye drops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312-34.
Herrero Vanrell R. Preservatives in ophthalmic formulations. Arch Soc Esp. Ophthalmol. 2007;82:531-2.
Noecker R. Ophthalmic preservatives: Considerations for long term use in patients with dry eye or glaucoma. Rev Ophthalmol. 2001;8:73-9.
Noecker R. Effect of common ophthalmic preservatives in ocular health. Adv Ther. 2001;18:205-15.
Clouzeau C, Golderfrog D, Riancho L, Rostene W, Baudouin C, Bregnole-Baudouin F. Hyperosmolarity potentiates toxic effect of benzalkonium chloride on conjunctival epithelial cells in vitro. Mol Vis. 2012;18:851-63.
Epstein S, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives in ophthalmic solutions. J Ocul pharmacol Ther. 2009;25:113-9.
De Saint Jean M, Brignole F, Baudouin F, Bauchet A, Feldmann G, Baudouin C. Effect of benzalkonium chloride on growth and survival of change conjunctival cells.Invest ophthalmol Vis Sci. 1999;40:619-30.
Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. European Journal of Pharmaceutics and Biopharmaceutics. 2002;53:263-80.
- Abstract Viewed: 804 times
- PDF Downloaded: 1187 times